Drug-Induced Hepatotoxicity in COVID-19

Abstract

Objective: The aim of this research is to map the scientific evidence on drug-induced hepatotoxicity in COVID-19.Method:This is an integrative literature review study, through a systematic search performed by the reviewers to identify all relevant studies on the different causes of liver failure in patients with COVID-19, published from June 16, 2021 to July 27, 2021.Results and Discussion: After analyzing the articles, six categories emerged, namely: 1) Drug-induced liver injury; 2) hepatotoxicity caused by Hydroxochloroquine in COVID-19; 3) the hepatotoxicity caused by Ivermectin in COVID-19; 4) hepatotoxicity caused by Tocilizumab in COVID-19; 5) hepatotoxicity caused by Azithromycin in COVID-19; 6) the hepatotoxicity caused by Remdesivir in COVID-19. Conclusion: COVID-19 has put the health systems of many countries under great pressure and has been particularly challenging due to the lack of predictive parameters and effective pharmacotherapies for the treatment of COVID-19 in advanced liver disease. Despite the common descriptions of liver enzyme alterations observed in patients with COVID-19, the frequency, intensity and impact of liver damage are discreet and of little clinical significance in relation to morbidity or mortality of this disease.